Nanoengineered Solutions: Advancements in Targeted Drug Delivery and Theranostics

Dear Colleagues,

In recent years, the intersection of nanotechnology and medical science has given rise to transformative innovations. As defined by medical regulatory agencies, “nanotechnology, i.e., controlling the shape and size of materials at nanometer scale,” “can be used to create products with a nanomaterial in the finished dosage form,” where a nanomedicine product is engineered to have or present properties of nanoscale dimension(s). Over the last couple of decades, we have witnessed the exponential growth of nanoscience biological and clinical applications, and our attention has been drawn to one of the most promising areas of pharmaceutical research: “Nanomedicine and Nanobioengineering.”

Targeted drug delivery holds the key to revolutionizing therapeutic interventions. The ability to precisely direct therapeutic agents to specific sites within the body not only maximizes efficacy but also minimizes side effects. Nanoengineered solutions play a pivotal role in this paradigm shift towards patient-centered precision therapies, offering tailored approaches to drug delivery that promise breakthroughs not only in the diagnosis and treatment of a variety of pathological conditions, such as cardiovascular diseases, cancer, diabetes, immunological, inflammatory, and neurodegenerative disorders, but also offering protection against some of their genetic or epigenetic etiologies.

The fusion of nanotechnology and pharmaceuticals has unlocked unprecedented possibilities in enhancing the precision, physicochemical stability and efficiency, bioavailability, and safety of targeted nano-delivery systems.

We are pleased to invite you to this Special Issue on " Nanoengineered Solutions,” which aims to serve as an open forum where researchers may share their current findings, evaluations, and expert opinions in this ever-growing area of “Nanoengineered Solutions: Advancements in Targeted Drug Delivery."

Thanks to the current nanomedical evolution, the scope of this scientific development area has expanded to explore a diverse range of topics within the realm of nanoengineered targeted drug delivery systems. Areas of interest include, but are not limited to, innovative nanocarrier technologies, site (cellular and intracellular)-specific delivery, hybrid nano-platforms, and nanocomposite (organic and inorganic/metalloid) nano-platforms.

The broad focus of this Special Issue explores various routes of administration, including both conventional (parenteral, topical, and oral) and less common (e.g., mucosal and ocular delivery, combination/coated medical devices, implants, and wearables) routes of administration, which can also be used for drug delivery and theranostic applications.

Here, we invite scholars and academic investigators to contribute their valuable insights and novel research, both in the form of original research or review article submissions, on the various aspects of nanoengineered solutions in targeted drug delivery development to help explain their unique properties and demonstrate their specific clinical advantages and prospects in pharmaceutical product development.

Prof. Dr. Tamer Elbayoumi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Nanotheranostics is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• nanoscale engineering
• nanomedicine
• disease prevention and treatment
• theranostic biomarkers
• precision/targeted nano-delivery platforms/systems/formulations
• targeted nano-theranostic applications
• personalized nanomedicine
• physico-chemical characterization
• bioavailability
• pharmacodynamics
• localized and systemic administration
• safety and efficacy

• Nanoengineered Solutions: Advancements in Targeted Drug Delivery in Molecules